Targeted therapy against the programmed cell death ligand-1 (PD-L1) blockade holds considerable promise for the treatment of different tumor types; however, little effect has been observed against gliomas thus far. Effective glioma therapy requires a delivery vehicle that can reach tumor cells in the central nervous system, with limited systemic side effect. In this study, we developed a cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma, the most aggressive type of brain *
SUMMARY
CD8
+
tissue-resident memory T cells (T
RM
) persist at sites of previous infection, where they provide rapid local protection against pathogen challenge. CD8
+
T
RM
expressing the α1 chain (CD49a) of integrin VLA-1 have been identified within sites of resolved skin infection and in vitiligo lesions. We demonstrate that CD49a is expressed early following T cell activation
in vivo,
and TGF-β and IL-12 induce CD49a expression by CD8
+
T cells
in vitro.
Despite this rapid expression, CD49a is not required for the generation of a primary CD8
+
T cell response to cutaneous herpes simplex virus (HSV) infection, migration of CD8
+
T cells across the epidermal basement membrane, or positioning of T
RM
within basal epidermis. Rather, CD49a supports CD8
+
T
RM
persistence within skin, regulates epidermal CD8
+
T
RM
dendritic extensions, and increases the frequency of IFN-γ
+
CD8
+
T
RM
following local antigen challenge. Our results suggest that CD49a promotes optimal cutaneous CD8
+
T
RM
-mediated immunity.
A series of thiazolopyrimidine derivatives was designed and synthesized as a Leishmania major pteridine reductase 1 (LmPTR1) enzyme inhibitor. Their LmPTR1 inhibitor activities were evaluated using the enzyme produced by Escherichia coli in a recombinant way. The antileishmanial activity of the selected compounds was tested in vitro against Leishmania sp. Additionally, the compounds were evaluated for cytotoxic activity against the murine macrophage cell line RAW 264.7. According to the results, four compounds displayed not only a potent in vitro antileishmanial activity against promastigote forms but also low cytotoxicity. Among them, compound L16 exhibited an antileishmanial activity for both the promastigote and amastigote forms of L. tropica, with IC50 values of 7.5 and 2.69 µM, respectively. In addition, molecular docking studies and molecular dynamics simulations were also carried out in this study. In light of these findings, the compounds provide a new potential scaffold for antileishmanial drug discovery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.